Neuphoria Therapeutics
NEUP
3 hedge funds and large institutions have $575K invested in Neuphoria Therapeutics in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
16% less capital invested
Capital invested by funds: $687K → $575K (-$112K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.63K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$1.72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Point72 Asset Management
Stamford,
Connecticut
| $277K | -$4.63K | -167 | -2% |
|
|
BI
2
BVF Inc
San Francisco,
California
| $178K | – | – | – |
|
|
WP
3
Woodline Partners
San Francisco,
California
| $120K | -$1.72K | -62 | -1% |
|
NEUP Hedge Fund Activity: Q2 2023 in Review
3 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q2 2023, worth a combined $575K — down 16% from $687K a quarter earlier.
Fund positioning in NEUP was balanced in Q2 2023: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Point72 Asset Management, cutting an estimated $4.63K.
- 3 institutional investors held Neuphoria Therapeutics (NEUP) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $575K of Neuphoria Therapeutics stock for Q2 2023, down 16% quarter-over-quarter.
- 0 funds opened new Neuphoria Therapeutics positions in Q2 2023 and 0 closed out.
- The largest Neuphoria Therapeutics seller in Q2 2023 was Point72 Asset Management, an estimated $4.63K sold.
Based on aggregated 13F filings for Q2 2023.